These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 11691826)
41. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728 [TBL] [Abstract][Full Text] [Related]
42. Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. Pierce A; Spooncer E; Wooley S; Dive C; Francis JM; Miyan J; Owen-Lynch PJ; Dexter TM; Whetton AD Oncogene; 2000 Nov; 19(48):5487-97. PubMed ID: 11114726 [TBL] [Abstract][Full Text] [Related]
43. Molecular insights into the Philadelphia translocation. Heisterkamp N; Groffen J Hematol Pathol; 1991; 5(1):1-10. PubMed ID: 2050600 [TBL] [Abstract][Full Text] [Related]
44. Model mice for BCR/ABL-positive leukemias. Honda H; Hirai H Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387 [TBL] [Abstract][Full Text] [Related]
45. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. Chen JY; Wang MC; Hung WC J Cell Physiol; 2011 Feb; 226(2):407-13. PubMed ID: 20717963 [TBL] [Abstract][Full Text] [Related]
46. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Li QF; Huang WR; Duan HF; Wang H; Wu CT; Wang LS Oncogene; 2007 Dec; 26(57):7904-8. PubMed ID: 17599053 [TBL] [Abstract][Full Text] [Related]
47. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. Horita M; Andreu EJ; Benito A; Arbona C; Sanz C; Benet I; Prosper F; Fernandez-Luna JL J Exp Med; 2000 Mar; 191(6):977-84. PubMed ID: 10727459 [TBL] [Abstract][Full Text] [Related]
48. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. Parada Y; Banerji L; Glassford J; Lea NC; Collado M; Rivas C; Lewis JL; Gordon MY; Thomas NS; Lam EW J Biol Chem; 2001 Jun; 276(26):23572-80. PubMed ID: 11323429 [TBL] [Abstract][Full Text] [Related]
49. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779 [TBL] [Abstract][Full Text] [Related]
50. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia]. Okabe M Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066 [TBL] [Abstract][Full Text] [Related]
51. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931 [TBL] [Abstract][Full Text] [Related]
52. CML mouse model in translational research. Peng C; Li S Methods Mol Biol; 2010; 602():253-66. PubMed ID: 20012403 [TBL] [Abstract][Full Text] [Related]
53. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Fernández de Mattos S; Essafi A; Soeiro I; Pietersen AM; Birkenkamp KU; Edwards CS; Martino A; Nelson BH; Francis JM; Jones MC; Brosens JJ; Coffer PJ; Lam EW Mol Cell Biol; 2004 Nov; 24(22):10058-71. PubMed ID: 15509806 [TBL] [Abstract][Full Text] [Related]
54. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient]. Skórski T Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203 [TBL] [Abstract][Full Text] [Related]
55. Chronic myelogenous leukemia as a model for the genetic basis of cancer. Cannistra SA Hematol Oncol Clin North Am; 1990 Apr; 4(2):337-57. PubMed ID: 2182595 [TBL] [Abstract][Full Text] [Related]
56. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505 [TBL] [Abstract][Full Text] [Related]
57. Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia. Press RD Mol Diagn; 2001 Sep; 6(3):211-3. PubMed ID: 11571715 [No Abstract] [Full Text] [Related]
58. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Tari AM; Arlinghaus R; Lopez-Berestein G Biochem Biophys Res Commun; 1997 Jun; 235(2):383-8. PubMed ID: 9199202 [TBL] [Abstract][Full Text] [Related]
59. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. Komatsu N; Watanabe T; Uchida M; Mori M; Kirito K; Kikuchi S; Liu Q; Tauchi T; Miyazawa K; Endo H; Nagai T; Ozawa K J Biol Chem; 2003 Feb; 278(8):6411-9. PubMed ID: 12456669 [TBL] [Abstract][Full Text] [Related]